Simon Corbett

Statistics

Publications

Citations

618

H-Index

Active since

2016

Affiliations

Spirogen (United Kingdom)(Current)

University College London

e-Therapeutics (United Kingdom)

Cancer Research UK

CRUK Lung Cancer Centre of Excellence

Simon Corbett is an author at Spirogen (United Kingdom) specializing in antibody-drug conjugates, cancer pharmacology, and antibody-drug conjugate therapy.

ORCID

Publications per year

2016–2024

Publications

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

Francesca Zammarchi, Simon Corbett, Lauren Adams et al. · Blood · 2018 · 181 citations · Full text

Pharmacy, Oncology, Pharmaceutics +13

Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer Payload

Arnaud Tiberghien, Jean-Noel Levy, Luke A. Masterson et al. · ACS Medicinal Chemistry Letters · 2016 · 167 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine

John A. Hartley, Michael Flynn, John P. Bingham et al. · Scientific Reports · 2018 · 129 citations · Full text

Medicine, Oncology, Pharmacology +14

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Song Cho, Francesca Zammarchi, David G. Williams et al. · Molecular Cancer Therapeutics · 2018 · 47 citations

Medicine, Oncology, Pharmacology +17

The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer–Containing Antibody–Drug Conjugates

Simon Corbett, Shiran Huang, Francesca Zammarchi et al. · Molecular Cancer Therapeutics · 2020 · 32 citations · Full text

Medicine, Oncology, Pharmacology +16

1–5 of 9